U.S. Department of Health & Human Services
National Institutes of Health
NCATS
This repository is under review for potential modification in compliance with Administration directives.
Dismiss
Return Home
Inxight
Drugs
Search Substances
Home
Browse Drugs
US Approved Drugs
Marketed Drugs
Investigational Drugs
All Substances
Search
Structure Search
Sequence Search
Downloads
About
Search Substances
CRIZANLIZUMAB
L7451S9126
US Approved Rx (2019)
First approved in 2019
General
Names
13
Classification
2
Identifiers
14
Subunits
4
Related Substances
1
CRIZANLIZUMAB
L7451S9126
US Approved Rx (2019)
First approved in 2019
General
Approval Year
2019
334
Names
13
Show
5
20
100
All
entries
Name
Type
Language
Name
Type
Language
CRIZANLIZUMAB
Official Name
English
SEG-101
Preferred Name
English
CRIZANLIZUMAB [MI]
Common Name
English
crizanlizumab [INN]
Common Name
English
IMMUNOGLOBULIN G2, ANTI-(HUMAN P-SELECTIN) (HUMAN-MUS MUSCULUS MONOCLONAL SELG1 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL SELG1 LIGHT CHAIN, DIMER
Systematic Name
English
Showing 1 to 5 of 13 entries
Previous
1
2
3
Next
Classification
2
Show
5
20
100
All
entries
Classification Tree
Code System
Code
Classification Tree
Code System
Code
Pharmacologic Substance
Pharmacologic Substance
[C1909]
Agent Affecting Blood or Body Fluid
NCI_THESAURUS
C78275
Designated/Approved
ORPHAN DRUG
Designated/Approved
Treatment of sickle cell disease
FDA ORPHAN DRUG
259708
Showing 1 to 2 of 2 entries
Previous
1
Next
Identifiers
14
Show
5
20
100
All
entries
Code System
Code
Type
Description
Code System
Code
Type
Description
DRUG CENTRAL
5365
PRIMARY
SMS_ID
100000174637
PRIMARY
USAN
FG-105
PRIMARY
RXCUI
2262279
PRIMARY
RXCUI
2262421
ALTERNATIVE
Showing 1 to 5 of 14 entries
Previous
1
2
3
Next
Subunits
4
Subunit 0
>SUBUNIT_0
Subunit 1
>SUBUNIT_1
Subunit 2
>SUBUNIT_2
Subunit 3
>SUBUNIT_3
Related Substances
1
ACTIVE MOIETY
L7451S9126
CRIZANLIZUMAB